FDA approves Imfinzi + chemo for treatment of adult patients with resectable early-stage (IIA-IIIB) EGFR/ALK WT NSCLC August 22, 2024
MHRA approves Zolbetuximab for the treatment of Claudin18.2+ve, HER2neg gastric/GEJ cancer August 21, 2024
Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer August 21, 2024
FDA Approves LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with R/R Cutaneous T-Cell Lymphoma August 13, 2024
DARZALEX FASPRO® (daratumumab & hyaluronidase-fihj)-based quadruplet regimen approved in the US for patients with newly diagnosed transplant-eligible multiple myeloma August 7, 2024
FDA grants Accelerated Approval to TECELRA® (afamitresgene autoleucel) for advanced MAGE-A4+synovial sarcoma in chemo-treated adults August 7, 2024
FDA expands Jemperli (dostarlimab) + chemo approval to all adult patients with primary advanced or recurrent endometrial cancer with demonstrated OS benefit August 6, 2024
RYBREVANT (amivantamab) + chemo approved in the EU for 1L treatment of patients with advanced NSCLC with activating EGFR ex 20 insertion mutations July 9, 2024
Tagrisso + chemo approved in the EU as new 1L treatment for patients with EGFR-mutated advanced lung cancer July 9, 2024
Tagrisso + chemo approved in China & Japan as 1st-line treatment for patients with EGFR-mutated advanced lung cancer July 1, 2024
US FDA Grants Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with R/R Follicular Lymphoma July 1, 2024
EMA accepts under Accelerated Assessment of MAA for UM171 Cell Therapy for patients with heme malignancies who lack a readily available suitable donor July 1, 2024
New Efficacy Data For RCC From KEYNOTE-B61 Added To Lenvima® (Lenvatinib) US Label Supporting Keytruda + Lenvima Indication For The 1L Treatment July 1, 2024
Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer based on CAPItello-291 results June 25, 2024
FDA Approves KEYTRUDA® + Carboplatin + Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma June 25, 2024
EU approves FRUZAQLA in Previously Treated Metastatic Colorectal Cancer Based on Results from Ph 3 FRESCO-2 Trial June 25, 2024
FDA grants Accelerated Approval to KRAZATI® (adagrasib) + Cetuximab for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic CRC June 25, 2024
US FDA Approves Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors June 18, 2024
Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer June 18, 2024
FDA approved blinatumomab in the consolidation phase of multiphase chemo for adult & pediatric patients with CD19+ve Ph–neg B-cell precursor ALL June 18, 2024
